semaglutide for kidney disease Ozempic picks up FDA indication to treat chronic Saving kidneys, hearts and lives':

Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding

This is why transparency and third-party testing are non-negotiable standards

[DOI] [PubMed] [Google Scholar] 48.Holman RR, Bethel MA, Mentz RJ, et al

H., Bkdal, T

Many frameworks cap loading at 8 weeks

Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm